OTCMKTS:ATBPF Antibe Therapeutics (ATBPF) Stock Price, News & Analysis $0.22 0.00 (0.00%) As of 10/23/2026 Add Compare Share Share Stock Analysis Stock AnalysisChart About Antibe Therapeutics Stock (OTCMKTS:ATBPF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Antibe Therapeutics alerts:Sign Up Key Stats Today's Range$0.22▼$0.2250-Day Range$0.22▼$0.2252-Week Range$0.11▼$0.89VolumeN/AAverage Volume27,352 shsMarket Capitalization$11.42 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Antibe Therapeutics Inc. is a Canadian biotechnology company focused on developing gastrointestinal-sparing anti-inflammatory and analgesic medicines. The company’s research has centered on hydrogen sulfide–releasing nonsteroidal anti-inflammatory drugs (NSAIDs), an approach intended to preserve the pain-relieving and anti-inflammatory benefits of conventional NSAIDs while reducing the risk of gastrointestinal injury and other treatment-related complications. Antibe’s lead drug candidate was ATB-346, a hydrogen sulfide–releasing derivative of naproxen developed for the treatment of acute and chronic pain. The company also worked on additional compounds, including ATB-352, as part of a broader pipeline targeting pain and inflammation. Its development programs were primarily directed toward pharmaceutical and clinical markets in North America and other international jurisdictions. Antibe was based in Toronto, Ontario, and its shares traded in Canada before also being quoted over the counter in the United States under the symbol ATBPF. The company encountered significant financial and operational challenges during the early 2020s, and public disclosures indicated that it suspended or wound down operations while pursuing creditor-protection and restructuring alternatives. Because its corporate status and leadership have changed over time, current management information may not be reliably available.AI Generated. May Contain Errors. Read More Receive ATBPF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Antibe Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ATBPF Stock News HeadlinesAPLIF Appili Therapeutics Inc.August 23, 2024 | seekingalpha.comANTIBE THERAPEUTICS INC (ATBPF) stock forecast and price targetJuly 19, 2024 | finance.yahoo.comElon Musk’s One Stock Retirement PlanStanley Druckenmiller once said you don't get rich diversifying into 50 mediocre assets - you get rich finding two or three asymmetric home runs. Analyst Jeff Brown says he has identified a new one, a single stock he calls Elon Musk's One Stock Retirement Plan.October 24 at 1:00 AM | Brownstone Research (Ad)Antibe Announces Appointment of ReceiverApril 24, 2024 | finance.yahoo.comAntibe Announces Appointment of ReceiverApril 24, 2024 | businesswire.comAntibe Reports Q3 2024 Interim Financial and Operating ResultsFebruary 14, 2024 | finance.yahoo.comAntibe Therapeutics reports Q2 resultsNovember 13, 2023 | msn.comAntibe Reports PK Results of First Clinical Study of Otenaproxesul’s New FormulationNovember 9, 2023 | finance.yahoo.comSee More Headlines ATBPF Stock Analysis - Frequently Asked Questions How have ATBPF shares performed this year? Antibe Therapeutics' stock was trading at $0.2156 at the beginning of 2026. Since then, ATBPF shares have increased by 0.0% and is now trading at $0.2156. How were Antibe Therapeutics' earnings last quarter? Antibe Therapeutics Inc. (OTCMKTS:ATBPF) posted its quarterly earnings data on Monday, November, 13th. The company reported ($0.07) earnings per share for the quarter, topping analysts' consensus estimates of ($0.09) by $0.02. How do I buy shares of Antibe Therapeutics? Shares of ATBPF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Antibe Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Antibe Therapeutics investors own include Aurora Cannabis (ACB), GoHealth (GOCO), Immunic (IMUX), 9 Meters Biopharma (NMTR), Alibaba Group (BABA), Rithm Capital (RITM) and Block (XYZ). Company Calendar Last Earnings11/13/2023Today10/24/2026Fiscal Year End3/31/2027Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolOTCMKTS:ATBPF CIKN/A Webwww.antibethera.com Phone(416) 922-3460FaxN/AEmployees11Year Founded2009Profitability EPS (Trailing Twelve Months)($0.25) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$14.73 million Net MarginsN/A Pretax MarginN/A Return on Equity-56.48% Return on Assets-29.07% Debt Debt-to-Equity RatioN/A Current Ratio10.06 Quick Ratio10.06 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.58 per share Price / Book0.37Miscellaneous Outstanding Shares52,981,000Free Float48,238,000Market Cap$11.42 million OptionableNot Optionable Beta0.51 Social Links 7 Blue-Chip Stocks to Add To Your Forever PortfolioA strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership. This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.Get This Free Report This page (OTCMKTS:ATBPF) was last updated on 10/23/2026 by MarketBeat.com Staff. From Our PartnersFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredHow I’m playing the AI melt-up (and down)Porter Stansberry says a powerful new market shift is forming and most investors are missing it entirely. I...Porter & Company | SponsoredSpaceX is worth trillions. This one's $14.It is not SpaceX, Tesla, Starlink, or Neuralink. But Elon's rocket company shows up in this stock's paperwork,...Behind the Markets | SponsoredElon Musk’s One Stock Retirement PlanStanley Druckenmiller once said you don't get rich diversifying into 50 mediocre assets - you get rich finding...Brownstone Research | SponsoredThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredYour book is insideBlane Markham and the Markham Trading Team are giving readers a limited window to download their options strat...TradeWins | SponsoredIf you keep cash in a U.S. bank account… read this NOWSince 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Antibe Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Antibe Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
